NasdaqCM:DMAC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has DiaMedica Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DMAC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: DMAC's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-12.1%

DMAC

-4.9%

US Biotechs

-3.6%

US Market


1 Year Return

102.9%

DMAC

33.8%

US Biotechs

36.4%

US Market

Return vs Industry: DMAC exceeded the US Biotechs industry which returned 33.5% over the past year.

Return vs Market: DMAC exceeded the US Market which returned 38.5% over the past year.


Shareholder returns

DMACIndustryMarket
7 Day-12.1%-4.9%-3.6%
30 Day18.2%-2.1%0.9%
90 Day59.5%6.6%6.7%
1 Year102.9%102.9%35.8%33.8%39.4%36.4%
3 Year76.5%76.5%19.1%13.0%53.4%43.5%
5 Year313.1%313.1%52.1%41.0%117.3%93.0%

Long-Term Price Volatility Vs. Market

How volatile is DiaMedica Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DiaMedica Therapeutics undervalued compared to its fair value and its price relative to the market?

5.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DMAC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DMAC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DMAC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DMAC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DMAC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DMAC is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is DiaMedica Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

40.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DMAC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DMAC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DMAC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DMAC is forecast to have no revenue next year.

High Growth Revenue: DMAC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DMAC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has DiaMedica Therapeutics performed over the past 5 years?

-38.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DMAC is currently unprofitable.

Growing Profit Margin: DMAC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DMAC is unprofitable, and losses have increased over the past 5 years at a rate of 38.8% per year.

Accelerating Growth: Unable to compare DMAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DMAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.9%).


Return on Equity

High ROE: DMAC has a negative Return on Equity (-35.53%), as it is currently unprofitable.


Next Steps

Financial Health

How is DiaMedica Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: DMAC's short term assets ($31.1M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: DMAC's short term assets ($31.1M) exceed its long term liabilities ($69.0K).


Debt to Equity History and Analysis

Debt Level: DMAC is debt free.

Reducing Debt: DMAC currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DMAC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DMAC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26% each year


Next Steps

Dividend

What is DiaMedica Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DMAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DMAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DMAC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DMAC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DMAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Rick Pauls (49 yo)

11.08yrs

Tenure

US$1,503,386

Compensation

Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD1.50M) is above average for companies of similar size in the US market ($USD950.27K).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dietrich Pauls
President11.08yrsUS$1.50m0.16%
$ 282.5k
Scott Kellen
CFO & Company Secretary2.83yrsUS$677.81k0.066%
$ 112.7k
Harry Alcorn
Chief Medical Officer2.5yrsUS$778.30k0.044%
$ 75.7k
Edward Calamai
Consulting Head of Manufacturing1.08yrsno datano data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Management: DMAC's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dietrich Pauls
President11.08yrsUS$1.50m0.16%
$ 282.5k
James Parsons
Independent Director5.33yrsUS$83.42k0.012%
$ 20.6k
R. Giuffre
Independent Director10.5yrsUS$80.42k0.94%
$ 1.6m
George Bakris
Member of Kidney Scientific Advisory Board1.75yrsno datano data
Richard Pilnik
Independent Chairman6.58yrsUS$118.54k0.28%
$ 486.8k
Glenn Chertow
Member of Kidney Scientific Advisory Board1.75yrsno datano data
Rajiv Agarwal
Member of Kidney Scientific Advisory Board1.75yrsno datano data
Philip Bath
Member of Stroke Clinical Advisory Boardno datano datano data
Scott Kasner
Member of Stroke Clinical Advisory Boardno datano datano data
Paolo Madeddu
Member of Stroke Clinical Advisory Boardno datano datano data
John Volpi
Member of Stroke Clinical Advisory Boardno datano datano data
Aldo Peixoto
Member of Kidney Scientific Advisory Board1.75yrsno datano data

3.5yrs

Average Tenure

59yo

Average Age

Experienced Board: DMAC's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DMAC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.6%.


Top Shareholders

Company Information

DiaMedica Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DiaMedica Therapeutics Inc.
  • Ticker: DMAC
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$171.837m
  • Shares outstanding: 18.74m
  • Website: https://www.diamedica.com

Number of Employees


Location

  • DiaMedica Therapeutics Inc.
  • 2 Carlson Parkway
  • Suite 260
  • Minneapolis
  • Minnesota
  • 55447
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DMATSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2007
DMACNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDMar 2007
F2KADB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2007

Biography

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/28 00:10
End of Day Share Price2021/02/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.